Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05455021




Registration number
NCT05455021
Ethics application status
Date submitted
8/07/2022
Date registered
13/07/2022
Date last updated
16/01/2024

Titles & IDs
Public title
Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) After Sub-optimal Percutaneous Transluminal Angioplasty (PTA) or Atherectomy: REACTIVATE I
Scientific title
Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) After Sub-optimal Percutaneous Transluminal Angioplasty (PTA) or Atherectomy: REACTIVATE I
Secondary ID [1] 0 0
1061-002
Universal Trial Number (UTN)
Trial acronym
REACTIVATE I
Linked study record

Health condition
Health condition(s) or problem(s) studied:
PAD - Peripheral Arterial Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Combination Product - Vessel Restoration System (VRS)

Combination Product: Vessel Restoration System (VRS)
The VRS includes the following components:
VRS 10-8-10 Dimer Coated Balloon Catheter
VRS Light Fiber
VRS Light Source The VRS will collectively refer to all the components used to perform the procedure. Their specific product name will identify individual elements.
Intervention code [1] 0 0
Combination Product
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
An acute reduction in arterial dissections
Timepoint [1] 0 0
12 months
Primary outcome [2] 0 0
Primary Patency as assessed by Doppler Ultrasound (DUS) and freedom from CD-TLR at 1 Year
Timepoint [2] 0 0
12 months
Secondary outcome [1] 0 0
Technical Success
Timepoint [1] 0 0
12 months
Secondary outcome [2] 0 0
Procedural Success
Timepoint [2] 0 0
12 months
Secondary outcome [3] 0 0
Clinical Success
Timepoint [3] 0 0
36 months
Secondary outcome [4] 0 0
Safety Measure
Timepoint [4] 0 0
72 months
Secondary outcome [5] 0 0
Hemodynamic Improvement
Timepoint [5] 0 0
36 months
Secondary outcome [6] 0 0
Rutherford Classification
Timepoint [6] 0 0
36 months
Secondary outcome [7] 0 0
Quality of Life Measure
Timepoint [7] 0 0
72 months

Eligibility
Key inclusion criteria
Subjects for this study must meet all of the following general eligibility criteria

AND the answer must be "YES" to all general inclusion criteria:

1. Subject (or Legal Guardian) is willing and able to provide consent before any
study-specific tests or procedures are performed and agree to attend all required
follow-up visits.

2. Male or female subject of at least 18 years of age.

3. Chronic symptomatic lower limb ischemia defined as Rutherford classification 2, 3, or
4.

4. Has screen failed from the ACTIVATE II study due to the presence of Grade C or D
dissection(s).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Life expectancy, documented in the Investigator's opinion, of less than 1 year.

2. Cerebrovascular accident (CVA) or transient ischemic attack (TIA) or cardiac event
(e.g., PCI for STEMI/NSTEMI, unstable angina) within 6 months prior to the index
procedure.

3. Chronic renal insufficiency with serum creatinine = 2.5 mg/dL or eGFR <45 ml/min
within 30 days prior to the index procedure or treatment with peritoneal or
hemodialysis.

4. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 within 30 days
prior to the index procedure or has a history of bleeding diathesis.

5. Receiving oral or intravenous immunosuppressive therapy.

6. Subject has white blood cell (WBC) count < 3.0 (3,000 cells/mm3) within 30 days prior
to the index procedure.

7. History of major amputation in the target limb.

8. Any major intervention planned at the index procedure or within 30 days post-index
procedure including treatment of contralateral limb.

9. Subject is pregnant, breastfeeding, or planning to become pregnant in the next 30
days. Subjects (male and female) of childbearing potential must agree to use effective
birth control measures for 30 days after the index procedure.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/11/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/11/2026
Actual
Sample size
Target
50
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 0 0
Flinders Medical Center - Adelaide
Recruitment hospital [2] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Alucent Biomedical
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Feasibility Study of the Vessel Restoration System (VRS) for the Treatment of Atherosclerotic
Lesions in the Superficial Femoral Artery (SFA) and/or Popliteal Artery (PA) after
Sub-optimal percutaneous transluminal angioplasty (PTA) or Atherectomy: REACTIVATE I
Trial website
https://clinicaltrials.gov/ct2/show/NCT05455021
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries